Subgroup | Observed number of new cases of proteinuria | Person-years of follow-up | Rate of events per 1000 person-years | Rate ratios | p Value |
---|---|---|---|---|---|
Currently on Plaquenil | |||||
No | 11 | 699 | 15.7 | 1.0 (Ref) | |
Yes | 46 | 3783 | 12.2 | 0.8(0.4 to 1.5) | 0.44 |
Plaquenil, current and past | |||||
Never | 2 | 328 | 6.1 | 1.0 (Ref) | |
Past, but not current | 9 | 309 | 29.1 | 4.8 (1.0 to 22.2 | 0.045 |
Current, <6 months | 14 | 476 | 29.4 | 4.8 (1.1 to 21.3) | 0.037 |
Current 6+ consecutive months | 32 | 3236 | 9.9 | 1.6 (0.4 to 6.8) | 0.51 |
Proportion of cohort follow-up on plaquenil | |||||
<20% | 8 | 413 | 19.4 | 1.0 (Ref) | |
20–79% | 5 | 374 | 13.4 | 0.7 (0.2 to 2.1) | 0.51 |
80%+ | 35 | 3119 | 6.1 | 0.6 (0.3 to 1.2) | 0.16 |
Currently on ACE inhibitors/ARB* | |||||
No | 10 | 628 | 15.9 | 1.0 (Ref) | |
Yes | 24 | 1592 | 15.1 | 0.9 (0.5 to 2.0) | 0.89 |
Proportion of cohort follow-up on ACE inhibitors/ARB* | |||||
<20% | 10 | 509 | 19.7 | 1.0 (Ref) | |
20–79% | 5 | 485 | 10.3 | 0.5 (0.2 to 1.5) | 0.24 |
80%+ | 13 | 956 | 13.6 | 0.7 (0.3 to 1.6) | 0.38 |
*These analyses only include patients on antihypertension medications to control for hypertension.